“Argenx's Vyvgart Fails Phase 3 Trial for Sjögren's Disease, Dealing Blow to Expansion Plan” — what this page in the network covers. Argenx's blockbuster drug Vyvgart did not outperform placebo in a late-stage trial for Sjögren's disease, the company announced, marking an unusual setback for the Belgian-Dutch biotech. The Phase 3 study evaluated the drug in patients with the chronic autoimmune disorder, which causes dry eyes and mouth, fatigue, and joint pain. Vyvgart, already approved for myasthenia gravis, was being tested as a potential new treatment option for Sjögren's, a condition with limited approved therapies.
The failure raises questions about Argenx's strategy to expand Vyvgart into other autoimmune indications, where the drug's mechanism—blocking the neonatal Fc receptor to reduce pathogenic IgG antibodies—was expected to show broad efficacy. Analysts noted the miss could impact Argenx's growth outlook, as Vyvgart is the company's key revenue driver. This listing links straight to the original page, where the content is available in full.